Programming of cells for tolerogenic therapies

US10080789B2 - Programming of cells for tolerogenic therapies

The device promotes (a) initial DC programming to quench inflammation via recruitment and expansion of Tregs, and (b) subsequent release of a BMP-2 encoding ...

Programming of cells for tolerogenic therapies - Patent WO ...

Programming of cells for tolerogenic therapies ... This web page summarizes information in PubChem about patent WO-2011014871-A1. This includes chemicals ...

Programming of cells for tolerogenic therapies - Patent US ...

Programming of cells for tolerogenic therapies ... This web page summarizes information in PubChem about patent US-2019183992-A1. This includes chemicals ...

AU2010278702C1 - Programming of cells for tolerogenic therapies ...

AU2010278702C1 - Programming of cells for tolerogenic therapies - Google Patents. Programming of cells for tolerogenic therapies. Info. Publication number ...

Programming of cells for tolerogenic therapies - Dimensions

Re-imagining discovery and access to research: grants, datasets, publications, citations, clinical trials, patents and policy documents in one place.

Tolerogenic dendritic cells generated in vitro using a novel protocol ...

Induction and activation of regulatory immune cells using tolDC therapies is an expanding technology, which has been clinically tested in ...

Metabolic programming in dendritic cells tailors immune responses ...

It is being increasingly acknowledged that immune cells depend on certain metabolic traits to perform their functions and that the ...

Generation and characterisation of therapeutic tolerogenic dendritic ...

Objectives Tolerogenic dendritic cells (tolDCs) constitute a promising experimental treatment for targeting autoreactive T cells in autoimmune diseases, ...

Review Tolerogenic dendritic cells for reprogramming of lymphocyte ...

Dendritic cells in health and autoimmune disease · Generation of tolerogenic dendritic cells for the treatment of autoimmune diseases · Modulation of T cell ...

Programming dendritic cells to induce TH2 and tolerogenic responses

and tolerogenic responses is likely to result from studying different hierarchies of organization in the innate immune system (Fig. 1c). The cell can be ...

Tolerogenic Immunotherapy: Targeting DC Surface Receptors to ...

Dendritic cells (DCs) are well-established as major players in the regulation of immune responses. They either induce inflammatory or tolerogenic responses, ...

Challenges in tolerogenic dendritic cell therapy for autoimmune ...

Summary. Tolerogenic dendritic cells (tolDCs) are a promising strategy to treat autoimmune diseases since they have the potential to ...

Special Issue : Tolerogenic Cell-Based Therapy: Where We Stand?

Therapies based on adoptive transfer of regulatory cells (T, macrophages, and tolerogenic (tol)DC) entered the clinical arena in recent years with the goal to ...

Inducing immune tolerance with dendritic cell-targeting ... - Nature

In contrast to conventional immunosuppressive treatments, tolerogenic immunotherapy leverages the cells and function of the immune system to ...

Antigen-specific immunotherapy via delivery of tolerogenic dendritic ...

Many current treatments for multiple sclerosis have broad immunosuppressive effects. · Tolerogenic dendritic cells aim to restore immune ...

Comparative study of clinical grade human tolerogenic dendritic cells

The use of tolerogenic DCs is a promising therapeutic strategy for transplantation and autoimmune disorders.

Ex Vivo-Generated Tolerogenic Dendritic Cells: Hope for a Definitive ...

Current therapies for autoimmune diseases are immunosuppressant agents, which have many debilitating side effects. However, dendritic cells (DCs) can induce ...

and long-term tolerogenic effects intrinsic to autoreactive effector T ...

Immunotherapies are needed in the clinic that effectively suppress β cell autoimmunity and reestablish long-term self-tolerance in type 1 ...

Tolerogenic therapy - Wikipedia

Tolerogenic therapy aims to induce immune tolerance where there is pathological or undesirable activation of the normal immune response. This can occur, for ...

Programming dendritic cells to induce tolerogenic response and ...

In EAE, these cells lose their tolerogenic properties resulting in uncontrolled neuronal inflammation. Current therapies involve non-specific immune suppression ...